ICON Clinical Research Announces the Appointment of a Vice President and Global Head for the Infectious Diseases Therapeutic Area Group


Dublin, Ireland, 14th July 2010 – ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Jonathan M Fishbein, M.D. as Vice President and Global Head for the Infectious Disease Therapeutic Area Group at ICON Clinical Research. Dr. Fishbein, who has extensive experience in the planning and execution of clinical research in a broad range of therapeutic areas, will oversee the growth and management of the infectious disease portfolio.

Dr Fishbein joined ICON in 2009 after a distinguished career at the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, USA, where he served as the first Director of the Office for Policy in Clinical Research Operations at the NIAID's Division of AIDS from 2003–2005. From 2005–2009, he simultaneously held the positions of Special Assistant to the Deputy Director of the NIAID and Senior Fellow at the International Center for Research on Women. Prior to this, Dr Fishbein held various roles at PAREXEL International Corporation from 1993–2003, including Vice President of North American Medical Services from 1999–2003.

Dr Fishbein, a surgeon by training, received his medical degree from the Johns Hopkins University School of Medicine and was a Medical Staff Fellow at the National Cancer Institute (Immunology Branch) and a Fellow in Transplantation Immunology at the Transplantation Biology Research Center at the Massachusetts General Hospital and Harvard Medical School.

Commenting on the appointment, Dr. John Hubbard, Group President for global Clinical Research Services said: “We’re delighted to welcome Dr. Fishbein to ICON Clinical Research where he will oversee the strategic development of our burgeoning infectious disease therapeutic area, which complements our well established and growing vaccine business.  His wealth of clinical research experience across a broad range of therapeutic areas is a valuable asset to the team.”

Also announced today was the formation of a new Medical Technology (MedTech) Therapeutic Area Group (TAG). The formation of the MedTech TAG responds to the emerging global opportunity arising from the diverse application of Medical Technology, both as drug-device combinations and standalone Medical Devices, currently estimated at some 30,000+ potential clients. MedTech TAG helps identify, focus, and support the adaptive deployment of ICON’s core strengths into this novel sector, differentiated by both service quality and providing integrated client support over the full product development lifecycle.